The biotechnology company's Founded Entity, Gallop Oncology, reports favorable tolerability and strong efficacy in a Phase 1b trial of its lead candidate LYT-200 for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
The healthcare company has announced a change in shareholding, with Citigroup Inc. increasing its stake in the business.
The healthcare company has disclosed changes in shareholding, with Citigroup Inc. increasing its stake to over 6% of the voting rights.
The biotechnology company is presenting new data from its ongoing Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia at the American Society of Hematology Annual Meeting.
The biotechnology company presents new Phase 2b data demonstrating the potential of its IPF treatment to benefit older patients, a historically undertreated group.
The healthcare company has announced a change in its shareholding structure.
The healthcare company has announced a change in major shareholding, with Citigroup Inc. increasing its stake.
The healthcare company has announced a change in its major shareholding structure.
The healthcare company has announced a change in its major shareholding structure.
The healthcare company provides an update on regulatory matters.